In today’s tightly regulated life sciences environment, regulatory compliance is not merely an operational requirement—it is a strategic imperative. From early-stage development to global market authorization, regulatory integrity shapes the trajectory of your product’s success.
At ProRelix Research, we serve as a trusted partner in navigating this complexity. Our regulatory framework is built upon the pillars of ICH-GCP, U.S. FDA regulations, and globally recognized regulatory benchmarks—delivering end-to-end compliance solutions that drive precision, accelerate approvals, and mitigate risk.
Our operations are rigorously aligned with International Council for Harmonisation – Good Clinical Practice (ICH E6 R2) standards, globally acknowledged as the definitive framework for ethical and scientific integrity in clinical trials.
We uphold:
Absolute protection of participant rights, safety, and confidentiality
Harmonized protocols and SOPs across trial sites
Real-time data integrity and traceability
Comprehensive training and oversight of investigators and monitors
Through strict GCP adherence, we not only meet regulatory expectations—we elevate them
ProRelix Research operates at the nexus of science and regulation, embedding core ICH guidelines into every aspect of clinical development and submission preparation.
Structured and transparent clinical study reporting
Good Clinical Practice with a focus on quality-by-design and risk-based monitoring
The U.S. Food and Drug Administration (FDA) remains the benchmark for global regulatory compliance. At ProRelix Research, we offer comprehensive FDA regulatory support, underpinned by scientific acumen and procedural mastery.
We specialize in:
21 CFR Part 312 – IND submissions and maintenance
21 CFR Part 314 – NDA, BLA, and ANDA preparation
21 CFR Part 11 – Compliance with electronic records and digital signatures
Strategic engagement in pre-IND, Type B and C meetings, and regulatory briefing packages
Our deep familiarity with Fast Track, Breakthrough Therapy, Priority Review, and Orphan Drug Designation pathways ensures your innovations reach the market swiftly and compliantly.
Our experts navigate the nuances of regional authorities—from FDA, EMA, and CDSCO, to PMDA, TGA, and Health Canada—ensuring seamless submissions across borders.
Every deliverable we produce—protocols, study reports, regulatory filings—is audit-ready and scientifically substantiated.
We don’t just consult—we co-create success by aligning our regulatory insights with your development objectives.
The stakes are high. The regulations are complex. But with ProRelix Research, compliance becomes your strongest asset. We empower your clinical and commercial trajectory with regulatory precision, proactive oversight, and global readiness.
Partner with us to ensure your next submission isn’t just compliant—
It’s compelling, credible, and confidently approved.
Contact our business development team today.
Elevate your compliance. Accelerate your approvals. Expand your impact.
Be the first to know the latest trends in clinical research, real-world case studies, and industry secrets.
ProRelix Research is the rapidly growing Contract/ Clinical Research Organization (CRO) with multi-country service capability supporting phase 1, 2, 3, & 4 clinical trials of Pharma, Biotech, Biopharma, Medical Device, Nutraceutical & Herbal companies to conduct in the USA, India, Europe & South East Asia.
